At the news
? NEUTRALIMPACT 4/10 8-K filed Apr 7, 2026 at 07:05 ET
GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota to sponsor a phase 1a/1b clinical trial of its drug candidate GTB-5550 for advanced solid tumors. The company will fund up to $3.8 million over three years for the study, which remains in the early research phase.
- GT Biopharma entered into an Investigator Initiated Clinical Trial Agreement with the University of Minnesota
- The agreement supports a phase 1a/1b clinical trial of GTB-5550 for advanced solid tumors
- GT Biopharma will fund up to $3.8 million over three years for the study
- The trial is sponsored by the University of Minnesota, not GT Biopharma
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access